Tuesday, 18 Jun 2019

You are here

ACR Announces New Executive Vice President Steven Echard

The American College of Rheumatology (ACR) Board of Directors is pleased to announce that Steven C. Echard, IOM, CAE  is the new Executive Vice President (EVP) of the American College of Rheumatology. Echard was offered the position in March of this year after a comprehensive, nationwide search that was conducted prior to announcing the departure of long-time EVP Mark Andrejeski.

Echard had been serving as CEO of the American Association for The Study of Liver Diseases (ASSLD) since early 2014 prior to accepting the opportunity. During his tenure with ASSLD, Echard made many notable contributions that increased the organizations global footprint and long-term viability, including:

  • Redefining the organization’s strategic plan and increasing its member-based program offerings;
  • Introducing a new brand image and a robust communications program to support the new strategic focus;
  • Launching AASLD’s Foundation to support the research and training initiatives to advance the study of liver disease; and

Nearly doubling its membership while increasing its global engagement and outreach.

Prior to his role leading AASLD, Echard served as the Executive Director of the Rheumatology Research Foundation for nine years. Under his leadership, the Foundation grew from an operating budget of $3.5 million to an impressive $17 million budget with over $70 million in assets. He also held a number of leadership roles within the American College of Rheumatology prior to his tenure with the Foundation.

Echard is also an active member of the American Society of Association Executives (ASAE) and has served on the Board of Directors for their Center for Association Leadership for the past two years and in several key leadership roles for the 10 years leading up to his appointment.

“We are thrilled to have Steve return to ACR as our new EVP.  He brings a wealth of experience in association management, together with a real understanding of the complexity and range of our specialty.  We have no doubt that under his capable leadership, ACR will continue to grow and thrive,” said ACR President, Paula Marchetta, MD, MBA.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

EULAR 2019- Day 4 Report

Saturday June 15th was the last half-day at EULAR 2019 but was highlighted by the “late-breaking” (LB) presentations that were presented from the podium and by poster.

Below are the top “LB” presentations from EULAR this year:

Understanding Non-arthritic Rheumatic iRAEs

A better understanding of rheumatic immune-related adverse event phenotypes beyond inflammatory arthritis has been furthered by work from three abstracts presented at EULAR 2019 in Madrid.

Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis 

Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rheumatic and Musculoskeletal Medicine presented at EULAR 2019.

EULAR 2019 – Day 3 Report

The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019.

1. Genovese Vagal nerve stimulator in RA

2. Low dose steroids in Hand OA